Metsera to Present Research Highlighting its Next-Generation Obesity Portfolio at the 61st EASD Annual Meeting
Metsera (NASDAQ:MTSR), a clinical-stage biopharmaceutical company, will present important data from its obesity treatment portfolio at the 61st EASD Annual Meeting in Vienna, Austria (September 15-19, 2025). The company will showcase three key presentations, including a late-breaking presentation on MET-233i, their ultra-long acting amylin analog.
Chief Medical Officer Steve Marso highlighted the potential of their next-generation nutrient-stimulated hormone (NuSH) therapies, both as standalone treatments and in combinations. Key presentations will feature the pharmacokinetics and weight loss results of MET-233i, and preclinical data on combining MET-233i with MET-097i, their ultra-long acting GLP-1 receptor agonist, representing a first-in-category multi-NuSH combination approach to obesity treatment.
Metsera (NASDAQ:MTSR), azienda biofarmaceutica in fase clinica, presenterà dati rilevanti sul proprio portafoglio per il trattamento dell'obesità al 61° Congresso Annuale EASD a Vienna, Austria (15-19 settembre 2025). Verranno proposte tre comunicazioni principali, inclusa una presentazione late-breaking su MET-233i, il loro analogo dell'amylina a lunga durata d'azione.
Il Chief Medical Officer Steve Marso ha sottolineato il potenziale delle terapie NuSH (ormoni stimolati dai nutrienti) di nuova generazione, sia come trattamenti singoli sia in combinazione. Le presentazioni chiave mostreranno la farmacocinetica e i risultati sulla perdita di peso di MET-233i, oltre ai dati preclinici sulla combinazione di MET-233i con MET-097i, il loro agonista del recettore GLP-1 ultra-long acting, che rappresenta un approccio multi-NuSH di prima categoria per il trattamento dell'obesità.
Metsera (NASDAQ:MTSR), una compañía biofarmacéutica en fase clínica, presentará datos relevantes de su cartera para el tratamiento de la obesidad en la 61.ª Reunión Anual de la EASD en Viena, Austria (15-19 de septiembre de 2025). La compañía expondrá tres presentaciones clave, incluida una comunicación de última hora sobre MET-233i, su análogo de amilina de acción ultra prolongada.
El Director Médico Steve Marso resaltó el potencial de sus terapias NuSH (hormonas estimuladas por nutrientes) de nueva generación, tanto como tratamientos individuales como en combinaciones. Las presentaciones principales incluirán la farmacocinética y los resultados de pérdida de peso de MET-233i, y datos preclínicos sobre la combinación de MET-233i con MET-097i, su agonista del receptor GLP-1 de acción ultra prolongada, que representa un enfoque pionero de combinación multi-NuSH para el tratamiento de la obesidad.
Metsera (NASDAQ:MTSR), 임상 단계의 바이오제약사인 이 회사는 비만 치료 포트폴리오에 대한 주요 데이터를 제61회 EASD 연례회의에서 발표합니다(2025년 9월 15–19일, 오스트리아 비엔나). 회사는 주요 발표 세 건을 선보이며, 그중 하나는 초장기 지속형 아밀린 유사체인 MET-233i에 대한 레이트브레이킹 발표입니다.
최고의학책임자 스티브 마르소는 차세대 영양자극 호르몬(NuSH) 치료제가 단독 요법 및 병용 요법 모두에서 지닌 잠재력을 강조했습니다. 주요 발표는 MET-233i의 약동학 및 체중 감소 결과와, 초장기 지속형 GLP-1 수용체 작용제인 MET-097i와의 병용에 대한 전임상 데이터를 다루며, 이는 비만 치료를 위한 최초의 카테고리형 다중 NuSH 병용 접근법을 의미합니다.
Metsera (NASDAQ:MTSR), une société biopharmaceutique en phase clinique, présentera des données importantes sur son portefeuille de traitements de l'obésité lors du 61e Congrès annuel de l'EASD à Vienne, Autriche (15-19 septembre 2025). La société proposera trois présentations clés, dont une communication de dernière minute sur MET-233i, leur analogue d'amyline à action ultra-prolongée.
Le directeur médical Steve Marso a souligné le potentiel de leurs thérapies de nouvelle génération stimulées par les nutriments (NuSH), aussi bien en monothérapie qu'en association. Les présentations majeures porteront sur la pharmacocinétique et les résultats de perte de poids de MET-233i, ainsi que sur des données précliniques combinant MET-233i avec MET-097i, leur agoniste ultra-longue durée d'action du récepteur GLP‑1, représentant une approche inédite de combinaison multi‑NuSH pour traiter l'obésité.
Metsera (NASDAQ:MTSR), ein biopharmazeutisches Unternehmen in der klinischen Phase, wird wichtige Daten aus seinem Portfolio zur Behandlung von Adipositas auf dem 61. EASD-Jahreskongress in Wien, Österreich (15.–19. September 2025) vorstellen. Das Unternehmen präsentiert drei zentrale Beiträge, darunter eine Late-Breaking-Präsentation zu MET-233i, ihrem ultra-langwirksamen Amylin-Analogon.
Chief Medical Officer Steve Marso hob das Potenzial der nächsten Generation von nährstoff‑stimulierbaren Hormontherapien (NuSH) hervor, sowohl als Monotherapien als auch in Kombinationen. Zu den Hauptvorträgen gehören die Pharmakokinetik und Gewichtsverlustdaten von MET-233i sowie präklinische Daten zur Kombination von MET-233i mit MET-097i, ihrem ultra-lang wirkenden GLP‑1‑Rezeptoragonisten, was einen ersten kategorieübergreifenden Multi‑NuSH‑Kombinationsansatz zur Behandlung von Adipositas darstellt.
- None.
- None.
NEW YORK, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, will present clinical and preclinical data from its portfolio of next-generation ultra-long acting, scalable, and combinable therapies at the 61st Annual Meeting of the European Association for the Study of Diabetes (EASD) held September 15-19, 2025, in Vienna, Austria.
“As we progress our pipeline of ultra-long acting next-generation nutrient-stimulated hormone, or NuSH, therapies, we are encouraged by the opportunity to leverage our investigational medicines both as monotherapies and in combination with each other,” said Steve Marso, M.D., Chief Medical Officer at Metsera. “Our late-breaker highlights the initial clinical results for our ultra-long acting amylin analog MET-233i, showcasing a potential best-in-class profile. We also have two preclinical presentations, including one highlighting how MET-233i can be combined with MET-097i, our ultra-long acting GLP-1 receptor agonist, in a first-in-category multi-NuSH combination. We look forward to presenting these findings to the scientific community at this year’s EASD Annual Meeting.”
Presentation Details:
Late-breaker, Clinical
Title: Pharmacokinetics, weight loss, and tolerability of the ultra-long acting amylin analog MET-233 (LB 14)
Presentation type: Late breaking oral presentation
Session: LBA OP 03: Is there a life after GLP-1?
Time/Date: Wednesday, September 17; 2:30 – 4:00 P.M. CEST
Location: London Hall
Preclinical
Title: Therapeutic NuSH cocktails: co-administration of an ultra-long acting PYY analogue engineered for tolerability and an ultra-long acting GLP-1 analogue induces significant weight loss in DIO mice (786)
Presentation type: Short oral discussion
Session: Session SO 066 Novel therapeutics – preclinical evidence for next-generation treatments
Time/Date: Thursday, September 18; 2:00 – 3:00 P.M. CEST
Location: Event F, Station 11
Title: MET-233 is a differentiated efficacious amylin analogue in preclinical studies, combinable with MET-097, an ultra-long acting GLP-1 receptor agonist (224)
Presentation type: Oral presentation
Session: Session OP 38: New drugs on the horizon?
Time/Date: Friday September 19; 10.00-11.00 A.M. CEST
Location: Paris Hall
About Metsera
Metsera is a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases. Metsera is advancing a broad portfolio of oral and injectable incretin, non-incretin and combination therapies with potential best-in-class profiles to address multiple therapeutic targets and meet the future needs of a rapidly evolving weight loss treatment landscape. Metsera was founded in 2022 and is based in New York City. For more information, please visit us at www.metsera.com and follow us on LinkedIn and X.
Metsera may use its website as a distribution channel of material information about the Company. Financial and other important information regarding the Company is routinely posted on and accessible through the Investors & News section of its website at investors.metsera.com. In addition, you may sign up to automatically receive email alerts and other information about the Company by using the “Email Alerts” option on the Investors & Media page and submitting your email address.
Forward-Looking Statements
This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Examples of such statements include, but are not limited to, statements relating to Metsera's expectations regarding participation and presentations at the 61st Annual Meeting of the European Association for the Study of Diabetes (EASD), its research and development activities, and statements regarding the efficacy, safety and potential regulatory progress of its investigational candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to the risks related to Metsera’s business outlined in Metsera’s filings with the Securities and Exchange Commission, including in the “Risk Factors” section of its Annual Report on Form 10-K for the year ended December 31, 2024. Forward-looking statements are not guarantees of future performance, and Metsera’s actual results of operations, financial condition and liquidity, and the development of the industry in which it operates, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that Metsera makes in this press release speak only as of the date of this press release. Metsera assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release
Contact:
Jono Emmett
Metsera
media@metsera.com
FAQ
What will Metsera (MTSR) present at the 61st EASD Annual Meeting 2025?
When and where is Metsera's late-breaking presentation at EASD 2025?
What is MET-233i and how is it different from other obesity treatments?
What are Metsera's NuSH therapies?
How is Metsera combining different obesity treatments in their research?
